4, 5% af patienterne vedvarende forhøjet alkalisk fosfatase under Raptiva- behandlingen sammenlignet med 1% hos placebopatienterne.
In large placebo-controlled clinical studies approximately 4.5% of patients developed sustained elevation of alkaline phosphatase throughout Raptiva therapy compared to 1% in placebo patients.